Current evidence does not establish what many years of repeated masseter treatment do to the jaw. A 2024 meta analysis reported a pooled 6.34% reduction in mandibular cortical thickness. A 2025 CT analysis from a randomised trial found no clinically significant density change after one or two sessions over twelve months. A 2026 morphology paper from the same trial found no detectable predefined shape changes. These are different endpoints, and the later papers are not independent replications. One year findings are reassuring within their scope, while cumulative effects remain uncertain.
Evidence Brief Conclusion
The best available human evidence does not support a settled claim in either direction. Short term trial findings are reassuring for the endpoints and exposure studied. They do not prove that repeated treatment over many years has no effect on bone, muscle bulk or facial balance.
The practical response is not alarm or automatic reassurance. It is to keep dose, interval, total cycles and changing lower face structure under review, and to stop when further reduction no longer makes clinical or aesthetic sense.
Evidence At A Glance
The table keeps each measured endpoint beside the population, exposure and limits that define it.
| Publication | Endpoint | Main finding | People, exposure and limits |
|---|---|---|---|
| 2024 systematic review and meta analysis | Mandibular cortical thickness | Pooled reduction of 6.34%. The condyle estimate was larger. | Human studies with small, varied samples. The condyle estimate came from only two studies. |
| 2025 randomised trial analysis | CT density at the condyle, premolar area and ramus | No clinically significant density change versus baseline or placebo | Prespecified subgroup of 123 adults; one or two sessions over twelve months. CT Hounsfield units do not directly measure absolute bone mineral density. Manufacturer funded. |
| 2026 morphology analysis | Bigonial width, cortical thickness at the masseter insertion, flare and gonial angles, and qualitative joint measures | No detectable difference from placebo in predefined measures | 187 adults from the same trial; one or two sessions over twelve months. Not an independent second trial. Manufacturer funded. |
How This Evidence Brief Was Built
This is a structured clinic evidence brief, not a formal systematic review or clinical practice guideline. The search began with the main recent human review, the later randomised trial publications, the registered trial record and Australian regulatory guidance. Each paper was checked for population, exposure, comparator, endpoint, timeframe, funding and stated limitations.
The conclusion is deliberately narrower than the papers themselves. A finding is only applied to the endpoint, people and timeframe actually studied. Where the research does not answer repeated exposure over several years, this brief says so rather than filling the gap with reassurance or speculation.
The editorial and evidence policy explains authorship, clinical review, AI assistance, corrections and conflict disclosure across the site.
What The 2024 Review Found
The 2024 Journal of Oral Rehabilitation review pooled human evidence and reported a 6.34% reduction in mandibular cortical thickness. The largest regional estimate was at the condyle, but that subset came from only two studies. Coronoid and ramus estimates were smaller.
This is a meaningful signal, not proof that every person will experience a permanent structural or visible change. The included studies were small and heterogeneous, so the pooled number should not be treated as a universal prediction.
What The 2025 Density Analysis Found
The 2025 Aesthetic Surgery Journal paper reported a prespecified analysis of 123 adults from randomised trial NCT02010775. Participants had one or two sessions over twelve months. CT measurements at the condyle, premolar area and ramus did not show clinically significant density changes against baseline or placebo.
This is useful evidence for the measured locations and study window. It is not an absolute bone mineral density measurement, and it does not establish what happens after many cycles over several years.
What The 2026 Morphology Analysis Added
The 2026 paper used the broader 187 person population from the same registered trial. It examined predefined measures including bigonial width, cortical thickness at the masseter insertion, flare angle, gonial angle and qualitative joint findings. It reported no detectable differences between active and placebo groups over twelve months.
This adds a useful set of shape and insertion site measurements. The paper also states that late emerging effects beyond the study window cannot be excluded.
Why The Later Papers Are Not Independent Replication
The 2025 and 2026 publications are not two separate randomised trials. Both analyse NCT02010775. One focused on a prespecified density subgroup. The other examined morphology in the broader trial population.
Separate publications can answer separate endpoint questions, but agreement within one trial is not the same as an independent research group reproducing the finding in a new population. That distinction affects how confidently the finding can be generalised.
Why Thickness, Density And Morphology Need Separate Answers
Cortical thickness is the width of the hard outer shell of bone. Density describes how compact the measured region appears. Morphology describes dimensions, angles and overall shape. One endpoint can remain stable while another changes.
A density paper does not negate a thickness signal, and a small pooled thickness signal does not establish a visible face shape change. The honest answer preserves each endpoint instead of compressing everything into the phrase “bone loss”.
What Lower Face Hollowing Can Mean
Some people describe a hollow, flat or gaunt lower face after extensive reduction. The masseter contributes to fullness around the jaw angle, so reduced muscle bulk can alter balance even without a demonstrated bone change.
Weight change, cheek support, natural anatomy and the amount of reduction also affect appearance. A visible hollow does not identify one cause by itself. This is why Corey assesses whether the muscle is adding useful support before recommending another cycle.
What Repeated Treatment Means In Practice
Muscle activity returns as the effect wears off. Treatment in the masseter typically lasts four to six months before activity returns fully.
If treatment is discontinued, the masseter typically returns toward its previous size over roughly six to twelve months. Response varies. After repeated cycles, some people find that return takes longer or that the muscle does not regain all of its former bulk.
- Dose, interval and total cycles are clinical decisions rather than automatic maintenance settings.
- The lower face should be reassessed before each further cycle.
- Existing muscle bulk may be contributing useful fullness or support.
- Waiting, referral or no treatment can be appropriate outcomes.
Risks To Discuss Before Another Cycle
Potential risks include bruising, pain, temporary chewing weakness, altered smile movement, asymmetry and more lower face hollowing than the person wanted. The individual risk discussion depends on anatomy, previous response, health history and the proposed plan.
Dental pain, jaw clicking, restricted movement or other functional symptoms may need dental or medical assessment rather than a cosmetic treatment pathway.
Funding And Conflicts Matter
The 2025 density paper and 2026 morphology paper report manufacturer sponsorship. Their disclosures include authors who were employees, stockholders, consultants or grant recipients. The sponsor participated in study design, research, analysis, interpretation and publication review.
That does not make the findings false. It does mean the evidence should be read with the funding context visible and should ideally be tested by independent groups using longer follow up and repeated exposure designs.
How Corey Uses This In Consultation
Corey Anderson RN looks at whether the masseter is contributing to the concern, whether existing bulk is supporting the lower face, how many previous cycles have occurred and whether more reduction still makes sense. Dental symptoms, jaw pain, clicking or functional concerns may need a different pathway.
The evidence does not create an automatic treatment recommendation. It supports a more careful conversation about uncertainty, cumulative history, facial structure and whether the likely benefit justifies another cycle.
What Would Change This Conclusion
Confidence would improve with independent prospective studies that follow people through multiple cycles for several years, record cumulative exposure, use validated density and thickness methods, and report visible facial changes alongside imaging. Studies should also publish prespecified endpoints, loss to follow up and funding relationships.
Until that evidence exists, the conclusion remains bounded: one year randomised findings are reassuring for their measured endpoints, while long term cumulative effects remain uncertain.
Evidence Brief Revision History
| Date | Change | Reason |
|---|---|---|
| 13 July 2026 | Separated the 2025 density paper from the 2026 morphology paper, corrected both DOI records, identified their shared trial and added funding disclosures. | The earlier version attached the morphology DOI to the density finding and did not make the shared trial clear. |
| 9 July 2026 | First clinic review published. | Created a patient facing summary of long term masseter questions. |
Continue Through The Evidence Series
Read how Core Aesthetics clinical evidence briefs are prepared, including how endpoints, timeframes, funding and uncertainty are recorded. For anatomy and planning, continue to masseter muscle explained, jaw muscle treatment planning and jaw muscle treatment Melbourne.
If you want help applying the evidence to your own history and lower face, read treatment suitability assessment or why a practitioner may recommend no treatment.
Sources And Clinical References
- Ahpra guidelines for registered health practitioners who perform non surgical cosmetic procedures
- TGA guidance for advertising health services involving therapeutic goods
- Journal of Oral Rehabilitation, 2024, doi:10.1111/joor.13590
- Aesthetic Surgery Journal, 2025, doi:10.1093/asj/sjaf167
- Aesthetic Surgery Journal, 2026, doi:10.1093/asj/sjag080
- Clinical trial record NCT02010775
Is this for you?
Consider booking a consultation if
- Adults researching repeated masseter treatment, lower face hollowing or jaw bone questions
- People comparing cortical thickness, density and morphology findings
- People deciding whether another treatment cycle still suits their lower face
- People who want uncertainty, study funding and timeframe limits stated clearly
This may not be for you if
- People seeking diagnosis for jaw pain, clicking, restricted movement or dental symptoms
- People who want an article to determine personal suitability
- People expecting treatment to be automatic after booking
- People seeking a fixed prediction about long term facial change
Suitability is confirmed at consultation. This list is general guidance, not a substitute for clinical assessment.
Frequently asked questions
Can masseter treatment permanently change my face shape?
Treatment reduces masseter muscle bulk, which can change fullness and support in the lower cheek and jaw area. If treatment is discontinued, the muscle typically returns toward its previous size over about six to twelve months, but response varies and return can be incomplete after repeated cycles. Research has reported some jaw bone measurements changing, while other measurements remained unchanged over one year. Evidence about many cycles over several years is not yet conclusive.
Does masseter treatment cause a hollow face?
Some people describe a hollow, flat or gaunt lower face after extensive reduction because the masseter contributes to fullness around the jaw angle. This appearance does not prove bone loss. Facial structure, cheek support, weight change and the amount of muscle reduction can all affect how the lower face looks. Corey considers whether existing masseter bulk is contributing usefully before recommending further treatment.
Is masseter treatment reversible?
Muscle activity returns as the effect wears off, and the masseter usually returns toward its previous size over roughly six to twelve months after treatment stops. Individual response varies. Return can take longer or remain incomplete after repeated cycles. That muscle response is separate from the still uncertain question of whether many years of reduced loading can affect the jaw bone.
What is the difference between cortical thickness and bone density?
Cortical thickness describes the width of the hard outer shell of bone. Density describes how compact the measured bone appears. Morphology describes shape and dimensions. These endpoints are related but not interchangeable, so an unchanged density result does not by itself prove that thickness or shape cannot change.
Do the 2025 and 2026 papers independently confirm each other?
No. They are separate analyses and publications from the same underlying randomised trial, NCT02010775. The 2025 paper examined density in a prespecified subgroup, while the 2026 paper examined predefined shape and thickness measures in the broader trial population. They add useful endpoint information, but they are not independent replication in a second group of patients.
Why does repeated treatment matter more than one or two sessions?
A one year study of one or two sessions can only describe that exposure and timeframe. It cannot establish what happens after many cycles over several years. Cumulative dose, treatment interval, changing facial structure and incomplete return of muscle bulk may all matter, which is why ongoing review is more appropriate than automatic maintenance.
Were the later masseter studies manufacturer funded?
Yes. The 2025 density paper and 2026 morphology paper report manufacturer sponsorship and disclose author employment, consultancy or grant relationships. Funding does not make a study invalid, but it is relevant context when judging design, endpoint choices, interpretation and the need for independent replication.
Who might be advised not to continue masseter treatment?
Further treatment may not be appropriate when the lower face is already narrow, the masseter is contributing useful support, the concern is mainly structural or dental, or the likely benefit does not justify additional reduction. A consultation may end with waiting, referral or no treatment. Treatment is never automatic after booking.